Get the Stockscreener App
8.42
1.45%
0.12
After Hours:
8.42
Fibrogen Inc stock is traded at $8.42, with a volume of 30,776.
It is up +1.45% in the last 24 hours and down -24.48% over the past month.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
See More
Previous Close:
$8.30
Open:
$8.31
24h Volume:
30,776
Relative Volume:
0.93
Market Cap:
$34.06M
Revenue:
$147.75M
Net Income/Loss:
$-284.23M
P/E Ratio:
-2.8737
EPS:
-2.93
Net Cash Flow:
$-317.54M
1W Performance:
-3.11%
1M Performance:
-24.48%
6M Performance:
+1.45%
1Y Performance:
-13.02%
1-Day Range:
$8.30
$8.6605
1-Week Range:
$8.30
$9.0999
52-Week Range:
$4.85
$21.94
Fibrogen Inc Stock (FGEN) Company Profile
Name
Fibrogen Inc
Sector
Industry
Phone
415-978-1200
Address
350 BAY STREET, SAN FRANCISCO, CA
Compare FGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
8.42 | 33.58M | 147.75M | -284.23M | -317.54M | -2.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-26-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-26-23 | Downgrade | Stifel | Buy → Hold |
| Jun-26-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-02-23 | Upgrade | Stifel | Hold → Buy |
| Jan-31-23 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-05-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-22-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-20-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-16-21 | Downgrade | Stifel | Buy → Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-07-21 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-21 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-02-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-20 | Initiated | Raymond James | Underperform |
| Jul-10-20 | Resumed | Stifel | Buy |
| May-01-20 | Initiated | Cowen | Market Perform |
| Apr-27-20 | Initiated | BofA/Merrill | Neutral |
| May-29-19 | Resumed | Goldman | Neutral |
| May-10-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-12-19 | Initiated | Piper Jaffray | Neutral |
| Feb-11-19 | Resumed | Stifel | Buy |
| Dec-19-18 | Upgrade | Citigroup | Neutral → Buy |
| Aug-08-17 | Reiterated | Leerink Partners | Outperform |
| Aug-08-17 | Reiterated | Stifel | Buy |
| Jul-21-17 | Downgrade | Goldman | Buy → Neutral |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Feb-11-16 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
| Dec-04-15 | Initiated | Citigroup | Buy |
| Sep-23-15 | Initiated | Lake Street | Hold |
| Jul-29-15 | Initiated | Citigroup | Buy |
| Jul-20-15 | Upgrade | Goldman | Neutral → Buy |
| Dec-09-14 | Initiated | Stifel | Buy |
View All
Fibrogen Inc Stock (FGEN) Latest News
What valuation multiples suggest for FibroGen Inc. stockWeekly Trade Analysis & Verified Momentum Watchlists - newser.com
Can FibroGen Inc. (1FG0) stock ride next bull market cycle2025 Pullback Review & Short-Term Trading Opportunity Alerts - newser.com
Can FibroGen Inc. (1FG0) stock deliver consistent EPS growthJuly 2025 Decliners & Weekly Top Gainers Alerts - newser.com
Why FibroGen Inc. stock remains resilientTrade Exit Report & Safe Capital Growth Tips - newser.com
Is FibroGen Inc. stock vulnerable to regulatory risks2025 Bull vs Bear & AI Powered Buy and Sell Recommendations - newser.com
Can FibroGen Inc. (1FG0) stock resist broad market declines2025 Volatility Report & Intraday High Probability Alerts - newser.com
Will earnings trigger a reversal in FibroGen Inc.Trade Volume Summary & Reliable Volume Spike Trade Alerts - newser.com
What drives FibroGen Inc stock priceCandlestick Trading Patterns & Free Take Advantage Of Momentum - earlytimes.in
Chart based exit strategy for FibroGen Inc.July 2025 Summary & Daily Technical Forecast Reports - newser.com
What hedge fund activity signals for FibroGen Inc. stockWeekly Trading Summary & Daily Growth Stock Investment Tips - newser.com
Fibrogen CEO Wettig Thane buys shares worth $33,749 By Investing.com - Investing.com Australia
Fibrogen CEO Wettig Thane buys shares worth $33,749 - Investing.com
Can FibroGen Inc. stock sustain institutional interestJuly 2025 Market Mood & Precise Swing Trade Entry Alerts - newser.com
Why FibroGen Inc. stock attracts global investorsPortfolio Update Summary & Safe Capital Investment Plans - newser.com
Can FibroGen Inc. stock outperform in 2025 bull marketWeekly Market Outlook & Target Return Focused Stock Picks - newser.com
Building trade automation scripts for FibroGen Inc.Earnings Recap Report & Weekly Top Gainers Alerts - newser.com
Should you hold or exit FibroGen Inc. nowJuly 2025 Intraday Action & AI Powered Buy and Sell Recommendations - newser.com
Is FibroGen Inc. reversing from oversold territoryQuarterly Portfolio Report & Weekly Chart Analysis and Guides - newser.com
Can FibroGen Inc. (1FG0) stock reach $200 price targetEarnings Recap Summary & Fast Entry Momentum Trade Alerts - newser.com
Is FibroGen Inc. (1FG0) stock expanding market penetrationMarket Trend Report & Smart Swing Trading Alerts - newser.com
Forecasting FibroGen Inc. price range with options dataJuly 2025 Short Interest & Low Risk Growth Stock Ideas - newser.com
What does recent volatility data suggest for FibroGen Inc.Weekly Stock Summary & Technical Confirmation Trade Alerts - newser.com
What to expect from FibroGen Inc. in the next 30 days2025 Breakouts & Breakdowns & Consistent Profit Alerts - newser.com
Is FibroGen Inc. stock ready for a breakout2025 Macro Impact & AI Driven Stock Movement Reports - newser.com
Fibrogen Inc Stock (FGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):